%0 Journal Article %A Andrew Holbrook %A Nicholas Tustison %A Freddie Marquez %A Jared Roberts %A Michael A. Yassa %A Daniel Gillen %A for the Alzheimer’s Disease Neuroimaging Initiative %T Anterolateral entorhinal cortex thickness as a new biomarker for early detection of Alzheimer’s disease %D 2019 %R 10.1101/19011825 %J medRxiv %P 19011825 %X Introduction Loss of entorhinal cortex (EC) layer II neurons represents the earliest AD lesion in the brain. Research suggests differing functional roles between two EC subregions, the anterolateral EC (aLEC) and the posteromedial EC (pMEC).Methods We use joint label fusion to obtain aLEC and pMEC cortical thickness measurements from serial MRI scans of 775 ADNI-1 participants (219 healthy; 380 MCI; 176 AD) and use linear mixed-effects models to analyze longitudinal associations between cortical thickness, disease status and cognitive measures.Results Group status is reliability predicted by aLEC thickness, which also exhibits greater associations with cognitive outcomes than does pMEC thickness. Change in aLEC thickness is also associated with CSF amyloid and tau levels.Discussion Thinning of aLEC is a sensitive structural biomarker that changes over short durations in the course of AD and tracks disease severity – it is a strong candidate biomarker for detection of early AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this work was provided by NIA T32 AG000096 (AH), NSF B2D-1612490 (FM), as well NIA R01AG053555 and P50AG05146 (DG and MAY). No authors or institutions received payment of services from a third party for any aspect of the submitted work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data for this manuscript are available upon reasonable request. %U https://www.medrxiv.org/content/medrxiv/early/2019/11/14/19011825.full.pdf